New oral formulation for the Treatment of Community-Acquired Lower Respiratory Tract Infections | CMAC

New oral formulation for the Treatment of Community-Acquired Lower Respiratory Tract Infections

Clinical Microbiology and Antimicrobial Chemotherapy. 2006; 8(4):350-358

Section
Type
Journal article

Abstract

Azithromycin is one of the most commonly used macrolides in the treatment of respiratory tract infections. Azithromycin is a popular antimicrobial due to a number of its unique pharmacokinetic and pharmacodynamic properties. This review describes the new oral azithromycin formulation. Characteristics of the novel formulation of azithromycin are higher dose strength in combination with slow release of antibiotic, that allows to use azithromycin as a single-dose therapy. Controlled clinical trials showed that efficacy and safety of single-dose therapy with azitromycin was comparable to those of standard antimicrobial treatment regimens.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared